Upsher-Smith Laboratories, a Midwest-based pharmaceutical company in the US, has opened a 270,000 sq ft greenfield manufacturing facility that offers contract manufacturing, packaging and serialisation.

Upsher-Smith will focus on up-to-date packaging, serialisation capabilities, and supporting contract manufacturing for third parties at its new manufacturing plant in Maple Grove, MN. The company will use its relationships with distributors and demonstrated track record in several key areas, such as FDA compliance and inspection history, Environmental Health & Safety performance, and customer service

Upsher-Smith's offerings include environmentally sustainable solvent and aqueous-based oral solid dosage (OSD) manufacturing in tablet or capsule form, powders, liquids, and suspensions. Serialised packaging solutions include OSD/liquid bottles, unit dose blisters and liquid cups, and powder filling in sachets, bottles, and cans. Outbound packaging configurations are also aggregated following the pending Drug Supply Chain Security Act (DSCSA) conformance standards.

Upsher-Smith also manufactures small, commercial batches of products destined for FDA submissions and clinical purposes in a nearby Pilot Plant, known as Plant B. As well, the company carries processing equipment and performs analytics.